Get the Stockscreener App
2.65
3.52%
0.09
After Hours:
2.65
Goodrx Holdings Inc stock is traded at $2.65, with a volume of 1.18M.
It is up +3.52% in the last 24 hours and up +11.81% over the past month.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
See More
Previous Close:
$2.56
Open:
$2.55
24h Volume:
1.18M
Relative Volume:
0.53
Market Cap:
$897.49M
Revenue:
$796.85M
Net Income/Loss:
$30.44M
P/E Ratio:
31.47
EPS:
0.0842
Net Cash Flow:
$93.88M
1W Performance:
+9.05%
1M Performance:
+11.81%
6M Performance:
-2.21%
1Y Performance:
-30.63%
1-Day Range:
$2.55
$2.665
1-Week Range:
$2.415
$2.665
52-Week Range:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Name
Goodrx Holdings Inc
Sector
Industry
Phone
(855) 268-2822
Address
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.65 | 867.01M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
160.17 | 25.83B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
58.50 | 11.25B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.18 | 8.35B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
88.11 | 7.25B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
55.25 | 4.27B | 646.34M | -512.40M | 202.76M | -6.6871 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Underweight |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Aug-09-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-23-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-16-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-23 | Upgrade | DA Davidson | Neutral → Buy |
| Jul-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Dec-01-22 | Initiated | Citigroup | Buy |
| Nov-04-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-12-22 | Initiated | DA Davidson | Neutral |
| Jun-10-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-06-22 | Resumed | BofA Securities | Buy |
| Jun-01-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-10-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-10-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-10-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-11-22 | Initiated | Wells Fargo | Equal Weight |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Mar-15-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-22 | Reiterated | Barclays | Overweight |
| Mar-01-22 | Reiterated | BofA Securities | Neutral |
| Mar-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-01-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-01-22 | Reiterated | Evercore ISI | Outperform |
| Mar-01-22 | Reiterated | Goldman | Buy |
| Mar-01-22 | Reiterated | JP Morgan | Underweight |
| Mar-01-22 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-01-22 | Reiterated | SVB Leerink | Outperform |
| Jan-07-22 | Initiated | Goldman | Buy |
| Dec-21-21 | Initiated | Stephens | Overweight |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Aug-31-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-13-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| Apr-06-21 | Resumed | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Guggenheim | Buy |
| Nov-19-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-19-20 | Initiated | Barclays | Equal Weight |
| Oct-19-20 | Initiated | BofA Securities | Neutral |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Oct-19-20 | Initiated | Credit Suisse | Outperform |
| Oct-19-20 | Initiated | Deutsche Bank | Hold |
| Oct-19-20 | Initiated | Goldman | Neutral |
| Oct-19-20 | Initiated | JP Morgan | Neutral |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
| Oct-19-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-19-20 | Initiated | SVB Leerink | Outperform |
| Oct-19-20 | Initiated | UBS | Buy |
View All
Goodrx Holdings Inc Stock (GDRX) Latest News
SA analyst upgrades/downgrades: NVDA, META, GDRX, JPM - Seeking Alpha
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
GoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Holdings (GDRX) price target increased by 10.24% to 3.17 - MSN
The 5 Most Interesting Analyst Questions From GoodRx’s Q1 Earnings Call - Yahoo Finance
GoodRx (GDRX) CAO exercises RSUs and delivers shares to cover taxes - Stock Titan
GoodRx (NASDAQ: GDRX) executive exercises 44,779 RSUs, 19,726 shares for taxes - Stock Titan
GoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
GDRX Maintained by Citigroup -- Price Target Raised to $4.00 - GuruFocus
GoodRx Holdings Is Maintained at Buy by Citigroup - Moomoo
Jim Cramer on GoodRx: “I’m Going to Grant You That Spec” - Insider Monkey
Some May Be Optimistic About GoodRx Holdings' (NASDAQ:GDRX) Earnings - simplywall.st
GDRX (NASDAQ: GDRX) Form 144 — 43,100-share proposed sale - Stock Titan
Why Jim Cramer Says 'Pull The Trigger' On Chevron - Benzinga
GoodRx (GDRX) awards 54,494 RSUs to Chief Accounting Officer Thomas Chan - Stock Titan
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises - Investing.com Nigeria
TradingKey - TradingKey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA) - The Globe and Mail
GDRX Maintained by TD Cowen -- Price Target Raised to $4.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue - The Motley Fool
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2026 Earnings Call Transcript - Insider Monkey
GoodRx Earnings Call Highlights Pharma Direct Momentum - TipRanks
GoodRx (GDRX) Q1 2026 Earnings Call Transcript - The Globe and Mail
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com India
GoodRx Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Q1 2026 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
GoodRx Holdings, Inc. (GDRX) Q1 earnings match estimates - MSN
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx Reports First Quarter 2026 Results - pharmiweb.com
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
GoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales Expectations - Barchart.com
Goodrx Holdings Inc Stock (GDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Goodrx Holdings Inc Stock (GDRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
0.66%
4.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):